Kaerus is developing targeted therapeutics that address an underlying ion channel dysfunction in Fragile X syndrome that contributes to hyper-excitability of the central nervous system in these patients. Our unique mechanistic approach to targeting BK channels has enabled Kaerus to expand focus on other rare genetic syndromes linked to the KCNMA1 gene. You can learn more about Fragile X and these related syndromes below.